3. Duplicative Therapy

Combined administration of multiple DOACs should be avoided. Concomitant DOAC use results in additive factor Xa inhibition and prolonged prothrombin time (PT), which increases bleeding risk 1-7. No evidence demonstrating increased efficacy or augmentation of therapy from use of multiple DOACs currently exists.